Close Menu

NEW YORK – Dutch biotech startup Epify announced today that it has raised €500,000 ($547,000) in seed funding.

The firm will use the funding to develop a portfolio of biomarkers discovered by Maastricht University professor Manon van Engeland to detect colorectal cancer (CRC). Founded by Engeland, Epify anticipates offering the biomarkers for non-invasive diagnosis of CRC at the earliest stage possible to allow patients to benefit from therapeutic interventions while they are still healthy.  

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Economist reports that it is increasingly easier to analyze the metabolites people give off, potentially revealing personal information about them.

A controversial paper on the gender gap in science has been corrected, according to BuzzFeed News.

The Los Angeles Times reports that only a third of California students meet the state's new science standards.

In Science this week: evidence of interbreeding between the ancestors of West Africans and an unknown archaic human, and more.